The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | ATOMIC-Meso: pegargiminase in malignant pleural mesothelioma
Peter Szlosarek, MD, PhD, Barts Cancer Institute, London, UK, discusses findings from the Phase II/III ATOMIC-Meso trial (NCT02709512) of pegargiminase with chemotherapy in patients with non-epithelioid pleural mesothelioma. Patients were randomized to receive either pegargiminase or placebo with chemotherapy, and overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints respectively. Both the endpoints were successfully met, and an encouraging safety profile was additionally reported. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
